Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | PNP | P00491 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cladribine SCHEMBL2789344 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL29881889 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL3775 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL11949489 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL11948325 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL4527409 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL17367349 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL1697053 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL21303677 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 | |
| Cladribine SCHEMBL29355473 | 1.00 | PDE4D (1.00) | PDE4DPDE3APNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427743-A1 | ANTI-HEPATOMA-VIRUS AGENT | Kagoshima University (JP) | 2019-01-16 | — | — | EP | claimed |
| US-6271212-B1 | MIXTURE WITH CARRIER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2001-08-07 | — | — | US | claimed |
| US-10987372-B2 | Anti-hepatoma-virus agent | KAGOSHIMA UNIVERSITY (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | KAGOSHIMA UNIVERSITY (JP) | 2019-03-07 | — | — | US | disclosed |
| EP-3427743-A1 | ANTI-HEPATOMA-VIRUS AGENT | Kagoshima University (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-9914914-B2 | Polymerase capable of producing non-DNA nucleotide polymers | MEDICAL RESEARCH COUNCIL (GB) | 2018-03-13 | — | — | US | disclosed |
| WO-2017207986-A1 | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS | NUCANA BIOMED LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017201585-A1 | MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION | GENEA IP HOLDINGS PTY LTD (AU) | 2017-11-30 | — | — | WO | disclosed |
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20120197010-A1 | PROCESS OF MAKING CLADRIBINE | SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) | 2012-08-02 | — | — | US | disclosed |
| US-8012717-B2 | Method for the production of cladribine | EXPLORA LABORATORIES S.A. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-7855285-B2 | Methods for selective N-9 glycosylation of purines | BRIGHAM YOUNG UNIVERSITY (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100291632-A1 | Method for the production of cladribine | EXPLORA LABORATORIES S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | BRIGHAM YOUNG UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080025916-A1 | Tailored Treatment Suitable for Different Forms of Mastocytosis | AB SCIENCE | 2008-01-31 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-6271212-B1 | MIXTURE WITH CARRIER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101431-A1 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | TYMP, NSUN2, PNP | PDE4D 890/4885PDE3A 896/4885PNP 3/4885 |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | PDE4D 76/4885PDE3A 237/4885PNP 14/4885 |
| US-20120197010-A1 | PROCESS OF MAKING CLADRIBINE | PNP, CPSF1, NSUN2 | PDE4D 1506/4885PDE3A 1338/4885PNP 1/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | PDE4D 2010/4885PDE3A 1469/4885PNP 1526/4885 |
| US-20080207891-A1 | Methods For Selective N-9 Glycosylation of Purines | PNP, SLC29A2, SLC28A2 | PDE4D 1177/4885PDE3A 2408/4885PNP 1/4885 |
| US-10987372-B2 | Anti-hepatoma-virus agent | HAVCR2, HDGF, HDGFL3 | PDE4D 4594/4885PDE3A 4647/4885PNP 3116/4885 |
| US-20190070207-A1 | ANTI-HEPATOMA-VIRUS AGENT | HAVCR2, HDGF, HDGFL3 | PDE4D 4594/4885PDE3A 4647/4885PNP 3116/4885 |
| US-20080025916-A1 | Tailored Treatment Suitable for Different Forms of Mastocytosis | KIT, CMA1, CPA3 | PDE4D 1099/4885PDE3A 1580/4885PNP 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.